Condition: Antibody-Mediated Rejection · Kidney Transplantation · Biopsy-proven Histologic Scores · Sponsor: Alexion Pharmaceuticals, Inc.
The primary objective of this study is to evaluate the efficacy of ALXN2030 compared with placebo on biopsy proven histologic resolution in participants with active or chronic active antibody-mediated rejection (AMR) at Week 52.
This description comes directly from the study's public registry record.
Alexion Pharmaceuticals, Inc. (Sponsor) · 1-855-752-2356 · clinicaltrials@alexion.com
Always discuss trial participation with your own doctor first.
| Research Site | Birmingham, Alabama, United States | Recruiting |
| Research Site | Scottsdale, Arizona, United States | Recruiting |
| Research Site | Los Angeles, California, United States | Recruiting |
| Research Site | Orange, California, United States | Recruiting |
| Research Site | Tampa, Florida, United States | Recruiting |
| Research Site | Atlanta, Georgia, United States | Recruiting |
| Research Site | Kansas City, Kansas, United States | Recruiting |
| Research Site | Ann Arbor, Michigan, United States | Recruiting |
| Research Site | Detroit, Michigan, United States | Recruiting |
| Research Site | Livingston, New Jersey, United States | Recruiting |
| Research Site | New York, New York, United States | Withdrawn |
| Research Site | New York, New York, United States | Recruiting |
+ 43 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06744647